...of viral vector-based therapies. Our participation in the Oncolytic Virotherapy Summit underscores our commitment to advancing the field and collaborating with companies developing innovative therapies to help patients in need....
...Gene Therapy Manufacturing & Commercialization event at booth #361. This is a ground-breaking event for manufacturing, commercialization and supply chain strategies. The event brings together industry leaders and experts to...
...6A (Biocity), 20520 Turku. sonja.lillhonga@biovian.com On what grounds and for what purpose will Biovian process your data? We process and maintain jobseekers’ personal data to fill vacant positions. We process...
...it ensures that the competence has remained within the company. A high number of people with higher education is another good indicator of the expertise within the CDMO. 3. Support...
ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101,...
...growth journey and help to further refine the strategy for the years to come.“ Dr. Uwe Gottschalk commented: “I am very grateful for the opportunity to support Biovian on its...
...of Global Business Development at Biovian” Dr. Knut Ringbom, CEO of Biovian, states. “His track record of driving business with both commercial and strategic success combined with a customer-centric mindset...
...are specified and agreed upon in discussions with the customer. Examples of QC analyses: Identity, potency, safety and purity analyses Protein analyses Potency analyses Cell-based assays Purity/Impurity analyses Compendial analyses,...
Biovian is delighted to announce the successful completion of a debt refinancing initiative and securing a new funding package with Eurazeo, a French investment company, to support GeneCity facility expansion....
